How does Trofinetide treat Rett syndrome?

What is Trofinetide's mechanism of action in treating Rett syndrome?

Trofinetide, developed by Ovid Therapeutics, is a synthetic analogue of the protein N-terminal fragment of insulin-like growth factor 1 (IGF-1). It targets the neurotrophic activity of IGF-1, which plays a crucial role in the development and maintenance of the nervous system.

[Citation: 1]

According to DrugPatentWatch.com, Trofinetide has been shown to enhance synaptic plasticity and neuroprotection in preclinical studies, indicating its potential in treating neurodevelopmental disorders like Rett syndrome. [2]

How does Trofinetide differ from other treatments for Rett syndrome?

Unlike other treatments for Rett syndrome, Trofinetide is a non-invasive, oral medication that targets the underlying cause of the disease, rather than just managing symptoms. This approach aims to slow down disease progression and potentially restore lost functions.

[Citation: 3]

What clinical trials have been conducted to evaluate Trofinetide's efficacy in treating Rett syndrome?

Phases 1, 2, and 3 clinical trials have been conducted to evaluate Trofinetide's safety and efficacy in treating Rett syndrome. The results have shown promising improvements in clinical measures, such as hand use and respiratory function.

[Citation: 4]

When will Trofinetide be available for patients with Rett syndrome?

Trofinetide has received FDA orphan drug designation for the treatment of Rett syndrome, but the exact date of its approval and availability is not yet determined.

[Citation: 5]

References:

1. Ovid Therapeutics. (n.d.). Trofinetide.
2. DrugPatentWatch.com. (n.d.). Trofinetide.
3. Ovid Therapeutics. (n.d.). Rett Syndrome.
4. ClinicalTrials.gov. (n.d.). Trials for Trofinetide in Rett Syndrome.
5. FDA. (n.d.). Orphan Drug Designations and Approvals.